Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study.
about
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessHigh and persistent HIV seroincidence in men who have sex with men across 47 U.S. citiesInter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infectionRunning in Place: Implications of HIV Incidence Estimates among Urban Men Who Have Sex with Men in the United States and Other Industrialized CountriesEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialAge and sex or gender (sex/gender) and HIV vaccine preparedness.Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical preventionAssessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.Age, race/ethnicity, and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States.Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.Using social networks to recruit an HIV vaccine preparedness cohortHIV vaccine preparedness studies in the organization for economic co-operation and development (OECD) countries.In "Step" with HIV Vaccines? A Content Analysis of Local Recruitment Campaigns for an International HIV Vaccine StudyRecruitment of Caribbean female commercial sex workers at high risk of HIV infection.Performance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection.The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study.A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.Association of site-specific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study.The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United StatesPrice, performance, and the FDA approval process: the example of home HIV testingCombined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmissionThe potential role of biomarkers in HIV preventive vaccine trialsA comparison of network-based strategies for screening at-risk Hispanic/Latino adolescents and young adults for undiagnosed asymptomatic HIV infectionFishermen as a Suitable Population for HIV Intervention TrialsCost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsEvaluation of a multiplex assay for estimation of HIV-1 incidence.Lessons drawn from recent HIV vaccine efficacy trials.Routine HIV screening in Portugal: clinical impact and cost-effectiveness.Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.The lifetime medical cost savings from preventing HIV in the United States.Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa.Challenges in the design of HIV prevention trials in the United States.Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in UgandaHIV incidence determination in the United States: a multiassay approach.Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trialsAn assessment of the feasibility and acceptability of a friendship-based social network recruitment strategy to screen at-risk African American and Hispanic/Latina young women for HIV infection.Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.
P2860
Q28474086-57F398FB-0A0D-4333-B5C0-65E5ABD73E99Q28482421-39E07588-7652-4D81-BC8C-7BD3E2D2B9DCQ28534491-58B0381F-3C9A-4CAA-B709-41E11EB4745DQ28972341-AF9AF335-76AB-493B-B455-6005A5A26AAAQ28972526-F701CBBB-29C1-4F43-9B16-EA4B2E0E2609Q30202232-FE9C531D-A0D7-459A-BDAA-2BA1EA8FF07EQ30206105-3DB5804A-D84D-491D-8F72-06C07FEB8D68Q30208996-889F1AEC-1406-436E-A1D8-8EA3CE072001Q30217421-C8861748-11B4-4F92-A09B-3C9D899C9D9BQ30223510-B9BAD48E-87F6-4D3A-B26A-E17C28D7FCB5Q30227795-B9F76005-5D6F-44C1-A715-13B511D7B22BQ30229401-6C4A4E19-7287-4AEA-9025-4EF3B3B26173Q30378981-19AFE948-30D0-48D0-8655-4037E4DA42AEQ33559528-27240D57-BCEE-4955-869F-EA102E8CBF4FQ33637675-F119562A-9B79-4357-BCEB-EB3AA9E6FD58Q33710740-84FB7E35-B2E3-4C15-AC00-D46F7297A772Q33714437-8074ABF7-93AF-46B2-9B3C-F0C7B6DBA680Q33812743-C87AC353-A75E-45BC-A30C-78DED274DD6CQ33822738-662C637F-0E37-4FB6-B82F-6F601213ADC8Q33855920-3C976292-237A-4257-9A46-068BA7AEFD48Q33961857-03F6E71E-57CD-4CB3-BDA4-BD4E64547F89Q33987424-62609816-2D51-4202-BCCC-7D0186D7E3AEQ34059957-DE6CA2E6-FBA1-4B78-9EB1-07C111E986F8Q34616379-1AADA9CC-CF49-4A6B-BCDD-3AAC23BBB31EQ34730059-BAD71718-5AD9-4E42-8A00-1C75CAF78BDAQ34735072-63C9B130-16CA-4BFD-916C-095C836D1F08Q34745421-CD8A39C5-51D3-4E3B-A237-EF47B230435DQ34816639-BC9A461F-FD83-4E7B-AE99-898BC8A266E0Q35075697-5B54A697-9344-47CD-880D-0CA3174AD20CQ35101431-C9EA847B-DF35-4AA2-BFD7-FC5F38D36636Q35177401-36757E68-E09A-4CA8-B6C5-4A66F52F5574Q35187935-1A34E952-32D4-4305-A2FC-C88B8B91F4A4Q35698044-03A4824B-8564-4567-9DCD-E7A8A5841252Q35819672-763D3453-2666-4BB6-B1B5-5A3FB584E0E5Q35863340-3BB5D71A-5847-4B89-A851-91AC2DAF5F06Q36495553-B4B7A8CD-46DD-4537-BD51-B0AB998762B5Q36582002-EF593A6F-F07C-47B1-91BE-146822329DBBQ36680971-1117F894-D33C-4610-8D66-A61472AF16D8Q36875336-3FA9C3CB-B654-4408-AF35-2A5F5F23EA4BQ36899651-FB6D44AC-0283-474B-9F31-1F86DE454056
P2860
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Are US populations appropriate ...... ET Vaccine Preparedness Study.
@ast
Are US populations appropriate ...... ET Vaccine Preparedness Study.
@en
type
label
Are US populations appropriate ...... ET Vaccine Preparedness Study.
@ast
Are US populations appropriate ...... ET Vaccine Preparedness Study.
@en
prefLabel
Are US populations appropriate ...... ET Vaccine Preparedness Study.
@ast
Are US populations appropriate ...... ET Vaccine Preparedness Study.
@en
P2093
P356
P1476
Are US populations appropriate ...... NET Vaccine Preparedness Study
@en
P2093
B A Koblin
D McKirnan
F N Judson
P304
P356
10.1093/AJE/153.7.619
P407
P577
2001-04-01T00:00:00Z